EOS imaging’s Micro Dose feature highlighted at EPOS 2015
April 15 2015 - 1:00PM
Business Wire
EPOS data presentations and a new installation
at Colorado Children’s Hospital reinforce EOS leadership in low
dose pediatric imaging
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the
pioneer in 2D/3D orthopedic medical imaging, today announced that
its new Micro Dose option is being highlighted at the European
Pediatric Orthopedic Society 34th Annual Meeting, April 15-18 in
Marseille, France.
Two of the four podium communications related with EOS benefits,
will present hospital’s findings confirming that Micro Dose affords
a drastic reduction in radiation exposure, and as such, should be
used for follow-up imaging in adolescent patients with idiopathic
scoliosis.
Concurrent with the Company’s EPOS presence is the announcement
that Children’s Hospital Colorado has installed an EOS system,
marking the first EOS installation in the state of Colorado. U.S.
News & World Report ranks Children’s Hospital Colorado seventh
in the nation in pediatric orthopedics. This installation further
cements EOS’ leadership position in pediatric imaging in the U.S,
and demonstrates the continued groundswell of EOS adoption in the
country,
Dr. Brice Ilharreborde, pediatric orthopaedist at Robert Debré
hospital in Paris, one of the two institutions presenting Micro
Dose results at EPOS, said, “EOS’ Micro Dose feature affords
surgeons and clinicians an outstanding tool to chart the safest
course of treatment for their patients. The research our team is
presenting at EPOS quantifies this reduction in exposure – a more
than five-fold reduction – as compared to already low-dose standard
EOS images. This reduction in exposure is critical for pediatric
patients in need of long-term treatment monitoring and follow-up
imaging, such as those with scoliosis.”
The research presented by the Robert Debré hospital team will be
published in the European Spine Journal.
Micro Dose enables a further drastic step towards the ALARA (As
Low As Reasonably Available) principle by bringing pediatric spine
follow up exams at a dose level equivalent to a week of natural
background radiation on Earth.
Marie Meynadier, CEO of EOS imaging, said, “Reducing radiation
exposure has been at the forefront of EOS imaging technology since
its inception. The data our leading users are providing about Micro
Dose at EPOS, in combination with a new installation at another
leading pediatric hospital in the U.S., are strong confirmations
that EOS imaging is becoming the gold standard in safe and
responsible pediatric imaging in the U.S. and worldwide.”
The EOS® system provides full-body stereo-radiographic images of
patients in functional positions, in both 2D and 3D. EOS exams
require a radiation dose 50% to 85% less than Digital Radiology and
95% less than basic CT scans.
For further information about the Company or EOS®, the first
full body, low dose 2D/3D imaging system, please visit
http://www.eos-imaging.com/.
EOS imaging has been chosen to be included in the new
EnterNext© PEA-PME 150 index, composed of 150 French companies and
listed on Euronext and Alternext markets in Paris.
EOS imaging is listed on Compartment C of Euronext ParisISIN:
FR0011191766 – Ticker: EOSI
Next press release: April 20 (2014 financial results and 2015
first quarter revenue)
About EOS imaging:
EOS imaging designs, develops, and markets EOS®, an innovative
medical imaging system based on technology that enabled George
Charpak to win the Nobel Prize for Physics, as well as associated
solutions. The Company is authorized to market in 47 countries,
including the United States (FDA), Japan and the European Union
(EU). As of December 31, 2014 the Group posted 2014 consolidated
revenue of €20.1 million and employed 107 people including an
R&D team of 39 engineers. The Group is based in Paris and holds
four subsidiaries in Besançon (France), Cambridge (Massachusetts),
Montreal (Canada) and Frankfurt (Germany), and offices in
Singapore.
Anne Renevot, +33 (0)1 55 25 61
24CFOinvestors@eos-imaging.comorNewCapFinancial
communication and investor relationsAntoine Denry/ Pierre Laurent,
+33 (0)1 44 71 94 91eosimaging@newcap.frorThe Ruth Group
(US)Press relations / Calvin Allen,
646-536-7002callen@theruthgroup.com
Eos (CE) (USOTC:EOSI)
Historical Stock Chart
From Apr 2024 to May 2024
Eos (CE) (USOTC:EOSI)
Historical Stock Chart
From May 2023 to May 2024